A share price of Sage Therapeutics Inc [SAGE] is currently trading at $7.90, up 4.08%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The SAGE shares have gain 7.34% over the last week, with a monthly amount drifted -5.39%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Sage Therapeutics Inc [NASDAQ: SAGE] stock has seen the most recent analyst activity on July 30, 2024, when TD Cowen downgraded its rating to a Hold and also revised its price target to $10 from $16. Previously, JP Morgan downgraded its rating to Neutral on July 25, 2024, and dropped its price target to $12. On May 29, 2024, Robert W. Baird initiated with a Neutral rating and assigned a price target of $15 on the stock. Citigroup started tracking the stock assigning a Sell rating and suggested a price target of $8 on May 29, 2024. BofA Securities downgraded its rating to a Underperform and reduced its price target to $14 on April 17, 2024. Deutsche Bank started tracking with a Hold rating for this stock on December 12, 2023, and assigned it a price target of $21. In a note dated August 08, 2023, Needham downgraded an Hold rating on this stock.
Sage Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $7.19 and $28.26. Currently, Wall Street analysts expect the stock to reach $45.22 within the next 12 months. Sage Therapeutics Inc [NASDAQ: SAGE] shares were valued at $7.90 at the most recent close of the market. An investor can expect a potential return of 472.41% based on the average SAGE price forecast.
Analyzing the SAGE fundamentals
Trailing Twelve Months sales for Sage Therapeutics Inc [NASDAQ:SAGE] were 97.24M which represents 249.80% growth. Gross Profit Margin for this corporation currently stands at 0.95% with Operating Profit Margin at -4.96%, Pretax Profit Margin comes in at -4.58%, and Net Profit Margin reading is -4.58%. To continue investigating profitability, this company’s Return on Assets is posted at -0.64, Equity is -0.6 and Total Capital is -0.77. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 7.68 points at the first support level, and at 7.46 for the second support level. However, for the 1st resistance point, the stock is sitting at 8.08, and for the 2nd resistance point, it is at 8.27.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Sage Therapeutics Inc [NASDAQ:SAGE] is 9.95. Also, the Quick Ratio is 9.95, while the Cash Ratio stands at 1.47. Considering the valuation of this stock, the price to sales ratio is 4.96, the price to book ratio is 0.77.
